Cash on Hand for Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's latest reported cash and short-term investments is $13.60B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
PFE
Currently viewingCash on HandSwitch metric
Latest period
$13.60B
YoY change
-33.6%
5Y CAGR
+2.2%
Peak year (2014)
$36.12B
Latest annual
$13.60B
Cash on Hand history chart for Pfizer (PFE) from 1985 to 2025
Cash on Hand history table for Pfizer (PFE) from 1985 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $13.60B | -33.6% | ||
| 2024 | $20.48B | +61.4% | ||
| 2023 | $12.69B | -44.2% | ||
| 2022 | $22.73B | -26.8% | ||
| 2021 | $31.07B | +154.2% | ||
| 2020 | $12.22B | +26.7% | ||
| 2019 | $9.65B | -48.8% | ||
| 2018 | $18.83B | -5.8% | ||
| 2017 | $19.99B | +12.0% | ||
| 2016 | $17.85B | -23.4% | ||
| 2015 | $23.29B | -35.5% | ||
| 2014 | $36.12B | +11.5% | ||
| 2013 | $32.41B | +0.0% | ||
| 2012 | $32.40B | +22.5% | ||
| 2011 | $26.45B | -5.6% | ||
| 2010 | $28.01B | +7.9% | ||
| 2009 | $25.97B | +9.4% | ||
| 2008 | $23.73B | -6.8% | ||
| 2007 | $25.48B | -8.1% | ||
| 2006 | $27.71B | +24.7% | ||
| 2005 | $22.23B | +11.7% | ||
| 2004 | $19.89B | +66.4% | ||
| 2003 | $11.95B | -4.8% | ||
| 2002 | $12.55B | +45.7% | ||
| 2001 | $8.62B | +25.5% | ||
| 2000 | $6.86B | +7.5% | ||
| 1999 | $6.39B | +311.5% | ||
| 1998 | $1.55B | +77.0% | ||
| 1997 | $877.00M | -23.7% | ||
| 1996 | $1.15B | +185.1% | ||
| 1995 | $403.30M | -72.3% | ||
| 1994 | $1.46B | +100.0% | ||
| 1993 | $729.40M | -42.0% | ||
| 1992 | $1.26B | -4.6% | ||
| 1991 | $1.32B | +51.4% | ||
| 1990 | $870.30M | +5.4% | ||
| 1989 | $825.40M | +2.2% | ||
| 1988 | $807.50M | -21.7% | ||
| 1987 | $1.03B | +158.7% | ||
| 1986 | $398.60M | -3.4% | ||
| 1985 | $412.60M | — |
Cash on Hand values are taken from Pfizer's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Pfizer (PFE) cash and short-term investments totalled $13.60B – plunged 33.6% year-over-year.
Through 2020–2025 (5 years), Pfizer cash and short-term investments delivered a +2.2% annualised rate; with the latest reading among the more recent periods of the dataset.
Between 2014 and 2025, Pfizer cash and short-term investments plunged 62.4%, falling from $36.12B to $13.60B.
The highest annual cash and short-term investments of $36.12B was reported in 2014. The lowest in the available history was $398.60M in 1986.
Within Healthcare, Pfizer (PFE) ranks 5th among 8 peers we track. The peer median for cash and short-term investments is $11.85B.
Pfizer Cash on Hand by Year
Pfizer Cash on Hand 2025: $13.60B
Pfizer cash and short-term investments in 2025 was $13.60B, plunged 33.6% below 2024.
Pfizer Cash on Hand 2024: $20.48B
Pfizer cash and short-term investments in 2024 was $20.48B, surged 61.4% from 2023.
Pfizer Cash on Hand 2023: $12.69B
Pfizer cash and short-term investments in 2023 was $12.69B, plunged 44.2% below 2022.
Pfizer Cash on Hand 2022: $22.73B
Pfizer cash and short-term investments in 2022 was $22.73B, declined 26.8% below 2021.
Pfizer Cash on Hand 2021: $31.07B
Pfizer cash and short-term investments in 2021 was $31.07B.
See more financial history for Pfizer (PFE).
Sector peers — Cash on Hand
Companies in the same sector as Pfizer, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Pfizer's cash and short-term investments?
- Latest reported cash and short-term investments for Pfizer (PFE) is $13.60B (period ending December 31, 2025).
How has Pfizer cash and short-term investments changed year-over-year?
- Pfizer (PFE) cash and short-term investments changed -33.6% year-over-year on the latest annual filing.
What is the long-term growth rate of Pfizer cash and short-term investments?
- Pfizer (PFE) cash and short-term investments compound annual growth rate is +2.2% over the most recent 5 years available.
When did Pfizer cash and short-term investments hit its highest annual value?
- Pfizer cash and short-term investments reached its highest annual value of $36.12B in 2014.
What was Pfizer cash and short-term investments in 2024?
- Pfizer (PFE) cash and short-term investments in 2024 was $20.48B.
What was Pfizer cash and short-term investments in 2025?
- Pfizer (PFE) cash and short-term investments in 2025 was $13.60B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
PFE Overview
Company profile, financial tools, and key metrics
PFE Revenue Counter
Earns $1,984 every second. See per minute, hour, and day.
PFE Earnings Counter
Earns $246.39 per second net profit. See per minute, hour, and day.
PFE Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
PFE What If Invested
What if you had invested $1,000? See historical returns from any date.
PFE How It Makes Money
Discover visual breakdown of $62.58B in revenue — where it comes from and where it goes.
PFE Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
PFE Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
PFE Daily Price Character
Steady · 46.3% historical win rate (green days). Streaks & record days.
PFE Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
PFE Stock Split History
6 splits on record. Dates, ratios, and cumulative multiple.
PFE Dividend Profile
Yield: 6.55%. Safety: 3/8. See full history.
PFE Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
PFE Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.